Aarti Pharmalabs Ltd (AARTIPHARM)
₹872.70
Mkt cap
₹7,914 Cr
P/E ratio
30.40
P/B
3.73
Div yield
0.40%
ROE
8.59%
ROCE
10.70%
EPS (TTM)
₹28.71
Book value
₹234
52W range
585–1,002
Sector
Healthcare
Price history
Previous close
Incorporated in 2019, Aarti Pharmalabs Ltd is a manufacturer of Pharmaceuticals and Nutraceuticals [1]
NSE AARTIPHARMBSE 543748
Health check
Constructive
ValuationFair
ProfitabilityAverage
GrowthModerate
TechnicalsBullish
52-week range
−12.94% from high₹873
₹585+49.18% from low₹1,002
Current
₹872.70
Prev close
₹927.65
Day
−5.92%
Price performance
1D
−5.89%
1W
+6.35%
1M
−10.26%
3M
+29.47%
6M
+23.11%
1Y
+4.14%
YTD
+17.60%
Financials
Revenue, profit & margin
P/E ratio
30.4×
AARTIPHARM is 12% below the sector median of 34.4×
AARTIPHARM30.4×
Sector median34.4×
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 440 | 449 | 506 | 555 | 458 | 538 | 564 | 386 | 418 | 432 | 583 | 536 | 610 | |
| Expenses | 352 | 353 | 388 | 459 | 364 | 409 | 418 | 293 | 344 | 330 | 470 | 400 | 475 | |
| Operating Profit | 88 | 96 | 118 | 96 | 94 | 129 | 146 | 93 | 74 | 102 | 113 | 136 | 135 | |
| OPM % | 20% | 21% | 23% | 17% | 20% | 24% | 26% | 24% | 18% | 24% | 19% | 25% | 22% | |
| Other Income | 1 | 1 | 2 | 2 | 4 | 5 | -2 | 2 | 0 | 2 | 14 | 8 | 5 | |
| Interest | 4 | 4 | 5 | 5 | 6 | 10 | 7 | 7 | 11 | 13 | 17 | 13 | 15 | |
| Depreciation | 18 | 19 | 19 | 20 | 21 | 23 | 23 | 23 | 25 | 29 | 28 | 30 | 31 | |
| Profit before tax | 67 | 74 | 96 | 74 | 72 | 101 | 115 | 65 | 39 | 63 | 82 | 101 | 95 | |
| Tax % | 23% | 29% | 32% | 25% | 24% | 26% | 23% | 24% | 28% | 24% | 25% | 25% | 25% | |
| Net Profit | 52 | 53 | 65 | 55 | 55 | 74 | 88 | 50 | 28 | 48 | 61 | 76 | 71 | |
| EPS in Rs | 5.72 | 5.82 | 7.20 | 6.12 | 6.03 | 8.16 | 9.75 | 5.46 | 3.08 | 5.29 | 6.74 | 8.40 | 7.88 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Sep 202639.66%Promoter
Promoters39.66%3.20
FIIs8.16%
DIIs8.40%1.18
Public43.78%2.04
Government0.01%
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,777.70 | 34.66 | 4,26,530 | 0.90% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹9,780.00 | 87.14 | 2,59,628 | 0.31% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| Torrent Pharma. | ₹4,613.40 | 80.83 | 1,75,479 | 0.82% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,405.50 | 97.00 | 1,29,972 | 0.08% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,245.50 | 25.52 | 1,24,239 | 0.08% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| Dr Reddy's Labs | ₹1,352.00 | 40.30 | 1,12,849 | 0.59% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,378.90 | 35.87 | 1,11,397 | 0.94% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Aarti Pharma | ₹872.70 | 30.40 | 7,914 | 0.40% | 71 | +161.46% | 610 | +45.93% | 10.70% |
| Median: 158 Co. | ₹426.38 | 34.39 | 1,921 | 0.08% | 14 | +22.08% | 175 | +18.92% | 15.12% |
Filings
Concall transcripts41
PPTOct 2026RECOct 2026PPTSep 2026TranscriptAug 2026PPTAug 2026RECAug 2026TranscriptJun 2026PPTJun 2026RECJun 2026TranscriptFeb 2026PPTFeb 2026RECFeb 2026TranscriptNov 2025PPTNov 2025RECNov 2025PPTSep 2025TranscriptAug 2025PPTAug 2025RECAug 2025TranscriptMay 2025PPTMay 2025RECMay 2025TranscriptFeb 2025PPTFeb 2025
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Newspaper Publication 30 OctAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 29 Oct - Audio recording of Q2 FY27 earnings conference call uploaded on website.Announcement under Regulation 30 (LODR)-Investor Presentation 29 OctUnaudited Financial Results For The Quarter And Half Year Ended September 30, 2026 - Uploading A Clear Version 28 Oct - Aarti Pharmalabs approved Q2 FY27 results, CFO resignation/appointment, and disclosed Rs 5,746 lakh stamp-duty contingent liability.Board Meeting Outcome for Outcome Of Board Meeting Held On October 28, 2026 28 Oct - Board approved Q2/H1 FY27 results and named Vibha Thakkar CFO from October 31, 2026, replacing Piyush Lakhani.